Quidditas Therapeutics

Quidditas raises €2.62M to accelerate development of pioneering genome editing technology

Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat complex, rare diseases while also opening new avenues for protein bioproduction and stem cell research 12 May 2025 -- Liège, Belgium -- Quidditas Therapeutics, a biotechnology company specialized in genome editing, today announces it has raised a total...